News|Articles|November 22, 2026

Five Under 5: Top Oncology Videos for the Week of 11/20

Author(s)OncLive Staff
Fact checked by: Chris Ryan
Listen
0:00 / 0:00

Key Takeaways

  • FDA declined ivonescimab plus chemotherapy in post–third-generation EGFR TKI NSCLC, judging PFS benefit insufficient without statistically significant OS, despite later nominal OS improvement and curve separation.
  • HER2 expression and PD-L1 CPS influence first-line HER2+ gastroesophageal therapy, with caution for zanidatamab plus chemotherapy without immunotherapy in IHC2+/ISH+ disease.
SHOW MORE

The top 5 OncLive TV videos of the week cover insights in NSCLC, HER2+ gastroesophageal cancer, low-grade glioma, HR+ breast cancer, and CML.

Welcome to The Five Under 5, your go-to roundup of the top 5 videos of the week.

These short videos are designed for busy oncologists to view on the go, and feature expert insights on breaking news, regulatory updates, practice-changing data shared at medical meetings, and other key topics in the realm of oncology.

Here’s what you may have missed:

HARMONi Survival Data and the FDA's Decision on Ivonescimab in Previously Treated EGFR-Mutated NSCLC: Natasha Leighl, MD

Natasha Leighl, MD, of Princess Margaret Cancer Centre, examined the FDA's November 2026 complete response letter for ivonescimab plus chemotherapy in patients with EGFR-mutated non–small cell lung cancer whose disease progressed on a third-generation EGFR TKI. In the phase 3 HARMONi trial (NCT06396065), ivonescimab plus carboplatin (Paraplatin) and pemetrexed (Alimta) improved median progression-free survival (PFS) vs placebo plus chemotherapy (6.8 vs 4.4 months; HR, 0.52; 95% CI, 0.41-0.66; P < .0001), but the overall survival (OS) analysis did not reach statistical significance (HR, 0.79; 95% CI, 0.62-1.01; P = .057). The FDA determined that a PFS benefit without a statistically significant OS improvement did not support a favorable benefit-risk profile. An updated analysis presented at the 2026 World Conference on Lung Cancer showed an OS HR of 0.76 (95% CI, 0.61-0.95; nominal P = .0151), and Leighl noted that the survival curves continued to separate with longer follow-up. She added that the phase 3 HARMONi-3 (NCT05899608) and HARMONi-7 (NCT06767514) trials comparing ivonescimab-based regimens with pembrolizumab (Keytruda)–based regimens would need to show an OS benefit to change practice.

Biomarkers to Guide First-Line Treatment in HER2+ Gastroesophageal Cancer: Yelena Y. Janjigian, MD

Yelena Y. Janjigian, MD, of Memorial Sloan Kettering Cancer Center, highlighted how HER2 expression level and PD-L1 status guided first-line treatment selection for HER2-positive gastroesophageal adenocarcinoma following the August 2026 FDA approval of zanidatamab-hrii (Ziihera)–based regimens. In the phase 3 HERIZON-GEA-01 trial (NCT05152147), zanidatamab plus chemotherapy, with or without tislelizumab-jsgr (Tevimbra), improved PFS and OS vs trastuzumab (Herceptin) plus chemotherapy. She noted that the comparator arm did not include pembrolizumab plus trastuzumab and chemotherapy, a US standard approved for tumors with a PD-L1 combined positive score (CPS) of at least 1 based on the phase 3 KEYNOTE-811 trial (NCT03615326). Janjigian cautioned against using zanidatamab plus chemotherapy without immunotherapy in patients with HER2 immunohistochemistry 2+/in situ hybridization–positive tumors, citing less favorable outcomes in that subgroup. Because the zanidatamab-based combinations require no minimum CPS, she added that they remained an option for patients with CPS 0 disease, although this is rare among HER2-positive tumors.

Early Predictors of Vorasidenib Response in IDH-Mutant Low-Grade Glioma: Francesco Bruno, MD, PhD

Francesco Bruno, MD, PhD, of the University of Turin, detailed findings from a prospective study of early predictors of response to vorasidenib (Voranigo) in 54 patients with IDH-mutant grade 2 glioma treated through an expanded access program, presented at the 2026 Society for Neuro-Oncology Annual Meeting. The objective response rate was 17.0% with bidimensional MRI (median time to response, 11.5 months), 28.3% with volumetric MRI (5.7 months), and 76.5% with 18F-DOPA PET (n = 13 of 17 measurable patients; 3.2 months). Among 12 patients with active seizures at treatment start, 11 (92%) had a seizure response, with a median time to response of 28 days. Early seizure response preceded tumor shrinkage on MRI at 3 and 6 months (P = .009 for both), consistent with exploratory analyses from the phase 3 INDIGO trial (NCT04164901). Bruno noted that layered monitoring could provide earlier evidence of drug activity in this slow-growing disease, with seizure control serving as the fastest marker of response.

Oral SERD Implementation in Early-Stage HR+ Breast Cancer: Neil Iyengar, MD

Neil Iyengar, MD, of Winship Cancer Institute of Emory University, outlined efficacy, sequencing, and tolerability considerations for oral selective estrogen receptor degraders (SERDs) in early-stage hormone receptor–positive breast cancer. In the phase 3 lidERA trial (NCT04961996), adjuvant giredestrant (Wilserdly) reduced the risk of invasive disease recurrence or death by 30% vs standard endocrine therapy among 4170 patients with estrogen receptor–positive, HER2-negative stage I to III breast cancer (HR, 0.70; 95% CI, 0.57-0.87; P = .0014). The 3-year invasive disease-free survival rates were 92.4% vs 89.6%, respectively, and treatment discontinuations due to adverse effects occurred in 5.3% vs 8.2% of patients. An FDA decision on giredestrant in this setting was anticipated by November 30, 2026. Iyengar noted that the optimal timing of switch strategies, potentially prompted by emergence of ESR1 mutations, remained an open question, and that better tolerability with oral SERDs could improve long-term adherence.

The Rationale Behind the OPTIC Trial in CML: Jorge Cortes, MD

Jorge Cortes, MD, of the O'Neal Comprehensive Cancer Center at the University of Alabama at Birmingham, reviewed the rationale behind and 5-year follow-up data from the phase 2 OPTIC trial (NCT02467270) of response-based ponatinib (Iclusig) dosing in chronic-phase chronic myeloid leukemia resistant to at least 2 prior TKIs or harboring a BCR::ABL1 T315I mutation. Patients were randomly assigned to starting doses of 45 mg (n = 94), 30 mg (n = 95), or 15 mg (n = 94) daily, with the 45- and 30-mg arms reduced to 15 mg upon achieving a BCR::ABL1 response of 1% or less. Twelve-month BCR::ABL1 response rates were 60%, 41%, and 40%, respectively, and were 64%, 25%, and 16% among patients with T315I mutations. Cortes noted that exposure-adjusted arterial occlusive event rates were similar with the 45- and 30-mg doses, suggesting that the 30-mg dose could compromise efficacy without improving safety. Starting at 45 mg and reducing to 15 mg upon response is now the approved label dosing, which he recommended in practice.


Related to this article